Delivering On Our Performance Objectives
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value,” said
| ($ in millions) | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | FY 2026 Expectations |
| Operating Expense Reduction from Prior Year Period, Excluding Restructuring Charges | (41)% | (38)% | (38)% | (22)% | Further reductions in Q4 |
| Net Cash Provided by Operating Activities | Positive for Q4 | ||||
| Cash, Cash Equivalents & Short-Term Investments | |||||
| Inventory | Maintain disciplined approach that aligns with demand and reflects improved contracting | ||||
| Debt | Remain debt free | ||||
Global Commercial Momentum and Continued U.S. Market Leadership
- In
Europe , in-market demand for VAZKEPA increased by an estimated 68% in Q3 2026 compared with Q3 2025, reflecting strong execution and increased investment by Recordati S.p.A. (“Recordati”) under our exclusive license and supply agreement. Momentum was driven by strong performance inSpain , theUK andItaly . Growth inEurope significantly exceeded the historical European growth rates achieved by Amarin before the partnership began in Q2 2025. - As of
September 30, 2026 , VASCEPA/VAZKEPA was commercially available in 22 countries worldwide, including 11 European countries through Recordati. The Recordati agreement covers 59 countries with patent protection for VASCEPA / VAZKEPA extending through 2039 in these markets. - VAZKEPA was launched into the private pay market in
Poland (non-reimbursed) during the month of October. Recordati is currently advancing pricing, reimbursement and market access activities to support planned launches in additional licensed markets. These launches, when completed, are expected to increase the number of countries where VAZKEPA will be commercially available. - Across our global partner network, in-market demand for VASCEPA/VAZKEPA increased by an estimated 55% in Q3 2026 compared with Q3 2025.
- In
the United States , the Company’s leading share of the IPE market was 47% in Q3 2026, reinforcing the power of VASCEPA’s clinical differentiation, the trust of prescribers and patients, our proven ability to reliably supply the market and the disciplined execution of our commercial team. - The Company expects
U.S . volumes to remain broadly stable for the remainder of FY 2026.
Financial Highlights
| ($ in millions) | Q3 2026 | Q3 2025 | % Change | 9 Mos. 2026 | 9 Mos. 2025 | % Change | |||
| Total Net Revenue | (20)% | (23)% | |||||||
| Operating Expenses | (44)% | (47)% | |||||||
| Operating Loss | 79% | 41% | |||||||
| Operating Margin % * | (6)% | (22)% | 16 pts | (20)% | (27)% | 7 pts | |||
| Net Income (Loss) | 103% | 52% | |||||||
| 1% | (16)% | 16 pts | (14)% | (23)% | 9 pts | ||||
| * Operating margin is calculated as operating loss divided by total net revenue | |||||||||
He continued, “We are encouraged by the in-market demand growth for VASCEPA/VAZKEPA across
Financial Performance
Comparisons to comparable 2025 periods, unless otherwise stated
Revenues
| ($ in millions) | Q3 2026 | Q3 2025 | % Change | 9 Mos. 2026 | 9 Mos. 2025 | % Change |
| Product Revenue, net: | ||||||
Rest-of-World (ROW) | (30)% (9)% 29% | (15)% (12)% 24% | ||||
| Total Product Revenue, net | (24)% | (12)% | ||||
| Licensing & Royalties | 139% | (73)% | ||||
| Total Net Revenue | (20)% | (23)% | ||||
Total Net Revenue:
Licensing and royalty revenue in Q3 2026 rose 139% to
Operating Expenses
Comparisons to comparable 2025 periods, unless otherwise stated
| ($ in millions) | Q3 2026 | Q3 2025 | % Change | 9 Mos. 2026 | 9 Mos. 2025 | % Change | |||
| COGS | (15)% | 17% | |||||||
| SG&A | (27)% | (39)% | |||||||
| R&D | 0% | (5)% | |||||||
| Restructuring | -- | NM | (90)% | ||||||
| Total Operating Expenses * | (44)% | (47)% | |||||||
| * Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses. NM - Not Meaningful | |||||||||
COGS: Decreased 15% to
SG&A: Decreased 27% to
R&D: Consistent with the prior year period.
A Stronger Platform for Strategic Value Creation
Exploring Additional Therapeutic Applications for IPE
On
The research presented by the Chief Investigator, Professor
“Our focus remains on patients and their unmet needs, and we are energized by the potential of new possibilities for VASCEPA suggested by the outcome of this study,” said
Third Quarter 2026 Financial Results Conference Call and Webcast Information
Amarin will host a conference call on October 28, 2026, at
About Amarin
At the Heart of
About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than thirty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021, marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Slovenia, Romania, Denmark and Austria.
United States Indications and Limitation of Use
VASCEPA is indicated:
- As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (= 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.
- As an adjunct to diet to reduce TG levels in adult patients with severe (= 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
- VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
- It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
- VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.
- Common adverse reactions in the cardiovascular outcomes trial (incidence =3% and =1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
- Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM
Europe
For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf
Globally, prescribing information varies; refer to the individual country product label for complete information.
Use of Non-GAAP Adjusted Financial Information
Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure is most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.
Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.
While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s outlook for achievements in 2026 and beyond; Amarin’s overall efforts to expand access and reimbursement to VASCEPA/VAZKEPA across global markets; expectations regarding potential market dynamics, payer behavior, and the competitive landscape; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2025 and subsequent quarterly reports on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Amarin Contact Information?
Media Inquiries:?
Amarin Corporation plc?
PR@amarincorp.com
Investor Inquiries:
Devin Sullivan & Conor Rodriguez?
The Equity Group on Behalf of Amarin??
devin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com
Investor.relations@amarincorp.com
-Tables to Follow-
| CONSOLIDATED BALANCE SHEET DATA | ||||||||
| ( | ||||||||
| Unaudited | ||||||||
| (in thousands) | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 156,512 | $ | 134,660 | ||||
| Restricted cash | 201 | 201 | ||||||
| Short-term investments | 166,867 | 167,929 | ||||||
| Accounts receivable, net | 111,573 | 126,832 | ||||||
| Inventory | 158,850 | 195,910 | ||||||
| Prepaid and other current assets | 18,872 | 24,350 | ||||||
| Total current assets | 612,875 | 649,882 | ||||||
| Operating lease right-of-use asset | 6,082 | 6,461 | ||||||
| Other long-term assets | 3,669 | 1,067 | ||||||
| Intangible asset, net | 11,455 | 13,365 | ||||||
| TOTAL ASSETS | $ | 634,081 | $ | 670,775 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 40,429 | $ | 45,355 | ||||
| Accrued expenses and other current liabilities | 134,707 | 149,104 | ||||||
| Total current liabilities | 175,136 | 194,459 | ||||||
| Long-Term Liabilities: | ||||||||
| Long-term operating lease liability | 5,353 | 6,080 | ||||||
| Other long-term liabilities | 9,180 | 10,955 | ||||||
| Total liabilities | 189,669 | 211,494 | ||||||
| Stockholders’ Equity: | ||||||||
| Common stock | 316,272 | 310,184 | ||||||
| Additional paid-in capital | 1,923,521 | 1,923,801 | ||||||
| (70,120 | ) | (67,360 | ) | |||||
| Accumulated deficit | (1,725,261 | ) | (1,707,344 | ) | ||||
| Total stockholders’ equity | 444,412 | 459,281 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 634,081 | $ | 670,775 | ||||
| CONSOLIDATED STATEMENTS OF OPERATIONS DATA | |||||||||||||||
| ( | |||||||||||||||
| Unaudited | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Product revenue, net | $ | 36,890 | $ | 48,558 | $ | 119,293 | $ | 136,210 | |||||||
| Licensing and royalty revenue | 2,660 | 1,112 | 7,600 | 28,217 | |||||||||||
| Total revenue, net | 39,550 | 49,670 | 126,893 | 164,427 | |||||||||||
| Less: Cost of goods sold | 23,369 | 27,462 | 77,954 | 66,728 | |||||||||||
| Gross margin | 16,181 | 22,208 | 48,939 | 97,699 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative (1) | 14,336 | 19,697 | 57,637 | 94,944 | |||||||||||
| Research and development (1) | 4,205 | 4,208 | 13,643 | 14,435 | |||||||||||
| Restructuring | — | 9,406 | 3,363 | 32,165 | |||||||||||
| Total operating expenses | 18,541 | 33,311 | 74,643 | 141,544 | |||||||||||
| Operating loss | (2,360 | ) | (11,103 | ) | (25,704 | ) | (43,845 | ) | |||||||
| Interest income, net | 2,371 | 2,783 | 7,845 | 8,277 | |||||||||||
| Other income, net | 304 | 205 | 1,583 | 372 | |||||||||||
| Income (loss) from operations before taxes | 315 | (8,115 | ) | (16,276 | ) | (35,196 | ) | ||||||||
| (Provision for) benefit from income taxes | (70 | ) | 377 | (1,641 | ) | (2,378 | ) | ||||||||
| Net income (loss) | $ | 245 | $ | (7,738 | ) | $ | (17,917 | ) | $ | (37,574 | ) | ||||
| Earnings (loss) per Ordinary Share: | |||||||||||||||
| Basic | $ | 0.00 | $ | (0.02 | ) | $ | (0.04 | ) | $ | (0.09 | ) | ||||
| Diluted | $ | 0.00 | $ | (0.02 | ) | $ | (0.04 | ) | $ | (0.09 | ) | ||||
| Weighted average Ordinary Shares: | |||||||||||||||
| Basic | 417,766 | 415,531 | 420,178 | 414,607 | |||||||||||
| Diluted | 427,856 | 415,531 | 420,178 | 414,607 | |||||||||||
| (1) - Excluding non-cash stock-based compensation, selling, general and administrative expenses were | |||||||||||||||
| RECONCILIATION OF NON-GAAP NET INCOME (LOSS) | ||||||||||||||||
| Unaudited | ||||||||||||||||
| Three months ended | Nine months ended | |||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net income (loss) for EPS1 - GAAP | 245 | (7,738 | ) | (17,917 | ) | (37,574 | ) | |||||||||
| Stock-based compensation expense | 1,377 | 2,354 | 5,773 | 12,720 | ||||||||||||
| Restructuring | — | 9,406 | 3,363 | 32,165 | ||||||||||||
| Litigation-Related Charges | — | — | 9,400 | — | ||||||||||||
| Licensing Agreement Fees | — | — | — | 5,038 | ||||||||||||
| ADS Ratio Change Fees | — | — | — | 2,015 | ||||||||||||
| Net income for EPS1 - non-GAAP | $ | 1,622 | $ | 4,022 | $ | 619 | $ | 14,364 | ||||||||
| 1basic and diluted | ||||||||||||||||
| Earnings per Ordinary Share: | ||||||||||||||||
| Basic - non-GAAP | $ | 0.00 | $ | 0.01 | $ | 0.00 | $ | 0.03 | ||||||||
| Diluted - non-GAAP | $ | 0.00 | $ | 0.01 | $ | 0.00 | $ | 0.03 | ||||||||
| Earnings per ADS: | ||||||||||||||||
| Basic - non-GAAP | $ | 0.08 | $ | 0.19 | $ | 0.03 | $ | 0.69 | ||||||||
| Diluted - non-GAAP | $ | 0.08 | $ | 0.19 | $ | 0.03 | $ | 0.69 | ||||||||
| Weighted average Ordinary Shares: | ||||||||||||||||
| Basic | 417,766 | 415,531 | 420,178 | 414,607 | ||||||||||||
| Diluted | 427,856 | 416,117 | 431,312 | 415,127 | ||||||||||||
Source: